

Proteon Therapeutics Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that the first patient has been treated in a second Phase 3 clinical study of investigational vonapanitase (formerly PRT-201), the company's lead product candidate. Here is a link to a previous article on this compound:

[http://www.jvascsurg.org/article/S0741-5214\(14\)00266-3/pdf](http://www.jvascsurg.org/article/S0741-5214(14)00266-3/pdf)

...